The Lancet Rheumatology
The Lancet Rheumatology
Targeting B-cell activation to tackle both patient-reported and systemic disease outcomes in Sjögren's disease [0.03%]
针对B细胞活化以应对干燥综合征患者的报告症状和全身性疾病结局
Dewi Rijnenberg,Safae Hamkour,Frank Redegeld et al.
Dewi Rijnenberg et al.
Mapping the infectious burden in VEXAS syndrome: a systematic review and rationale for prevention [0.03%]
VEXAS综合征感染负担的系统性文献回顾及预防策略的必要性分析
Valentine Ribier,Jérôme Hadjadj,Vincent Jachiet et al.
Valentine Ribier et al.
Infections are increasingly recognised as a major cause of morbidity and mortality in patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. We conducted a systematic review to characterise the infectious b...
VEXAS syndrome and immune-mediated rheumatic diseases: overlaps in clinical features and mechanisms [0.03%]
VEXAS综合征与自身免疫性风湿病的临床特征及机制重叠点分析
Arvind Kaul,Adam Al-Hakim,Helen Lachmann et al.
Arvind Kaul et al.
Vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic (VEXAS) syndrome is a newly identified disorder caused by an acquired monogenic somatic UBA1 gene mutation, affecting nuclear and cytoplasmic ubiquitination. This mutation trigger...
Rebecca Grainger,Lisa K Stamp
Rebecca Grainger
Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial [0.03%]
托法替布III期JUVE-RA研究的探索性分析：基线生物标志物与治疗反应之间的关联性研究
Venkatesh Krishnan,Stuart Y Keller,Christine Chew et al.
Venkatesh Krishnan et al.
Background: Baricitinib has previously been shown to improve clinical response in patients with juvenile idiopathic arthritis (JIA) in the JUVE-BASIS trial. In this post-hoc analysis we aimed to identify whether pharmacod...
Development and validation of a prognostic model for predicting the risk of allopurinol-induced severe cutaneous adverse reactions: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data [0.03%]
一项预测别嘌呤醇严重皮肤不良反应风险的预后模型的研制和验证：一项使用全科医疗、住院及死亡数据开展的回顾性新用户队列研究
Edoardo Cipolletta,Georgina Nakafero,Davide Rozza et al.
Edoardo Cipolletta et al.
Background: Allopurinol, the most prescribed urate-lowering drug, is a known cause of severe cutaneous adverse reactions. We aimed to develop and validate a model to assess the risk of allopurinol-induced severe cutaneous...
Biomarkers for juvenile idiopathic arthritis treatment response-have we identified them? [0.03%]
青少年特发性关节炎治疗反应的生物标志物-我们已经确定了吗？
Stephanie Ka Wong,Marinka Twilt
Stephanie Ka Wong
Dafna D Gladman
Dafna D Gladman